The ATX inhibitor from Galapagos Pharmaceuticals, GLPG1690 exhibited a good PK/PD profile in experimental animal model of PF and has entered Phase III clinical trials after completing the Phase II studies in IPF patients. The gene discussed is ENPP2; the disease is idiopathic pulmonary fibrosis.